Please login to the form below

Cytokinetics

This page shows the latest Cytokinetics news and features for those working in and with pharma, biotech and healthcare.

Roche reshuffles its executive committee, again

Prior to joining Genetech Sabry was chief executive officer for start-up biotech and was founder and chief executive of biopharma Cytokinetics.

Latest news

Amgen agrees to take Cytokinetics' heart failure drug into phase III

originator, Cytokinetics, which has been waiting for the big biotech to make a decision for several weeks. ... Cytokinetics said recently that meetings have been held with both the FDA and EMA to discuss the design of the outcomes study, which is due to
Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 
Roche buys rare disease firm Trophos in €470m deal

SMA therapy in development at Cytokinetics, while Biogen Idec and Isis Pharmaceuticals are also developing ISIS-SMNRx for the disease, a drug due to enter phase III soon.
Astellas forges $675m muscle alliance with Cytokinetics

Astellas has signed a major expansion of its collaboration with US biotech Cytokinetics to include neuromuscular diseases. ... It works in a similar way to Cytokinetics' tirasemtiv which is already in phase II trials for amyotrophic lateral sclerosis (ALS
Amgen drug misses endpoint in acute heart failure trial

A drug in development by Amgen and Cytokinetics to treat symptoms of heart failure has missed its primary endpoint in a phase II trial.

More from news
Approximately 4 fully matching, plus 4 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

Sale of Priority Review Voucher (PRV). 125. Cytokinetics/ Royalty Pharma. 4.5% royalty on global sales of omecamtiv mecarbil for heart failure (phase III).
Deal Watch July 2016

Real Relationships. Astellas and Cytokinetics have announced another extension to their agreement involving the development of their skeletal muscle activators, tirasemtiv and CK-2127107. ... 181. Cytokinetics/ Astellas. Tirasemtiv, CK-2127107 and
Astellas: Ten years young

option, while in muscle disease Astellas is working with Californian clinical-stage biopharmaceutical company Cytokinetics, looking at mechanisms for improving muscle strength.
Heart failure therapy embarks on a new era

In collaboration with Cytokinetics, Amgen is developing omecamtiv mecarbil, an activator of cardiac myosin that is designed to increase the duration of cardiac muscle contractility and improve cardiac muscle performance.
Deal Watch table for December 2014

Licence. 700. Cytokinetics / Astellas Pharma. CK-2127107, fast skeletal troponin activator, in Spinal Muscular Atrophy and other neuromuscular indications (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Featured jobs

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Account Manager / Senior Account Manager: 35, 000-40, 000

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Medical Writer: Great salary and benefits

Associate Director, Market Access & HEOR – North-West: Negotiable

Client Services Director – Medical Education Agency – North West...: Salary TBC

Senior Account Director development role to Business Director, H...: Excellent package

Associate Editorial Director – Med Comms – London: Salary TBC

Events Manager – Med Comms – Surrey: Salary TBC

Medical Writers Required – Cheshire: DOE

Associate Medical Director: Highly Competitive

Account Director: £48, 000 - £60, 000

Scientific Director / Editorial Team Leader: Great salary and benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Manager – Creative Healthcare Advertising – Central Lond...: Salary TBC

Senior Medical Writer: Competitive Salary

Director, Market Access / HEOR - North-West: Negotiable

Medical/ Scientific Director: Salary TBC

Senior Systematic Review Analyst - Oxford: Negotiable

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Senior Account Executive, London, Medical Communications: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...